AA
PRTK

ALPS Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

ALPS Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-56,149
Closed -$545K – 962
2018
Q3 		$545K Buy
56,149
+10,296
+22% +$104K ﹤0.01% 544
2018
Q2 		$468K Buy
45,853
+4,146
+10% +$46.9K ﹤0.01% 651
2018
Q1 		$542K Buy
41,707
+10,746
+35% +$160K ﹤0.01% 470
2017
Q4 		$554K Buy
30,961
+3,622
+13% +$75.6K ﹤0.01% 453
2017
Q3 		$686K Buy
27,339
+2,530
+10% +$58.9K ﹤0.01% 311
2017
Q2 		$598K Buy
+24,809
New +$548K ﹤0.01% 361

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

ALPS Advisors's PRTK Position: Q4 2018 in Review

ALPS Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 56,149 shares — an estimated $545K sold.

ALPS Advisors first reported a position in PRTK in Q2 2017 and held it in 6 quarters. The position peaked at $686K in Q3 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • ALPS Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 56,149 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $545K.
  • ALPS Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
  • ALPS Advisors's Paratek Pharmaceuticals, Inc. position peaked at $686K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.